#United States #New York #Securities Fraud #Rosen Law Firm #Dentsply Sirona

Dentsply Sirona Investors: Important Class Action Notice

The Rosen Law Firm, a prominent global law firm focused on investor rights, is urging shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY) to take note of an important class action suit concerning securities fraud. This lawsuit is applicable to those who purchased Dentsply Sirona common stock from February 28, 2022, through November 6, 2024, inclusive. Investors are advised that the deadline for leading the plaintiff's position in the case is January 27, 2025.

What This Means for Dentsply Sirona Investors

If you bought Dentsply Sirona's stock during the specified class period, you might qualify for compensation without incurring any out-of-pocket expenses through a contingency fee agreement. This is an excellent opportunity for investors seeking to hold the company accountable for alleged discrepancies and misleading statements issued during the class period.

To proceed with joining the class action, investors can visit the dedicated page on the Rosen Law Firm website or contact the firm directly for more information. It is crucial to act before the lead plaintiff deadline if you are interested in representing the class.

Background of the Case

The class action lawsuit claims that Dentsply Sirona made false claims and failed to disclose critical issues. Specifically, it is alleged that the company targeted vulnerable, low-income individuals who lacked proper dental care access, leading to many patients signing up for treatment programs, like Byte. These patients often had underlying dental issues that made them unsuitable for the treatment offered.

Further claims suggest that the thirst for growth in Byte sales pressured employees to sell products to these contraindicated patients. Reports indicated that many Byte patients suffered injuries, which Dentsply Sirona knew about but did not adequately investigate or report to the U.S. Food and Drug Administration (FDA) as required by law. The firm had reportedly failed to put in place necessary systems to inform the FDA, resulting in substantial harm to investors when the reality of the situation was disclosed.

Why Choose Rosen Law Firm

Rosen Law Firm is highly experienced in handling securities class actions, having achieved notable success in previous cases, including prestigious settlements involving Chinese companies. Ranked repeatedly among the top law firms for the number of settlements, the firm has recovered hundreds of millions for investors over the years. It has garnered accolades from organizations like Lawdragon and Super Lawyers and has seen its founding partner acknowledged for excellence in the field.

Investors are encouraged to carefully choose their legal representation, ensuring they work with firms that have substantial experience and capabilities in leading securities litigation. Rosen Law Firm prides itself on offering dedicated legal support, demonstrating a track record of handling investor rights matters effectively.

Next Steps for Investors

Dentsply Sirona investors can take affirmative steps by joining the ongoing class action. For more details, visit Rosen Law Firm's official site. Alternatively, they can reach Phillip Kim, Esq. at 866-767-3653 or email pkim@rosenlegal.com for their inquiries. It's essential to involve expert counsel as the timeline for participating is limited.

Conclusion

The implications of this lawsuit extend beyond mere financial compensation. For many investors, it symbolizes a stand against corporate misconduct and a step towards ensuring transparency and accountability in business practices. Those who feel they were misled by Dentsply Sirona during their time as shareholders should not hesitate to explore this opportunity of legal recourse to safeguard their rights and interests in the future.